April 27, 2024
Stocks & Bonds
[EQUITIES] ‘Genexine maintains lead on growth hormone’
[THE INVESTOR] Genexine’s competitive edge in developing long-acting growth hormone drug for children has sharpened as clinical trials of its rivals are failing, said Meritz Securities on Sept. 22.
 |
Its main rival Versartis’ drug candidate has failed to prove non-inferiority during phase 3 clinical trials, said analyst Lee Tae-yeong.
Genexine, on the other hand, has announced a successful result from the phase 2 trials of its GX-H9 last month, remaining in the lead, explained the analyst, but did not suggest a rating or a target price.
By Hwang You-mee (glamazon@heraldcorp.com)
